

Jaen Juan C.  
Form 4  
March 01, 2013

**FORM 4**

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549**

OMB APPROVAL

OMB Number: 3235-0287  
Expires: January 31, 2015  
Estimated average burden hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person \*  
Jaen Juan C.

2. Issuer Name and Ticker or Trading Symbol  
ChemoCentryx, Inc. [CCXI]

5. Relationship of Reporting Person(s) to Issuer

(Check all applicable)

(Last) (First) (Middle)  
C/O CHEMOCENTRYX, INC., 850 MAUDE AVENUE  
(Street)

3. Date of Earliest Transaction (Month/Day/Year)  
02/27/2013

\_\_\_\_ Director \_\_\_\_\_ 10% Owner  
 Officer (give title below) \_\_\_\_\_ Other (specify below)  
SVP, Drug Discovery & CSO

MOUNTAIN VIEW, CA 94043  
(City) (State) (Zip)

4. If Amendment, Date Original Filed(Month/Day/Year)

6. Individual or Joint/Group Filing(Check Applicable Line)  
 Form filed by One Reporting Person  
 Form filed by More than One Reporting Person

**Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned**

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)	4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V Amount (A) or (D) Price			
Common Stock	02/27/2013		M	2,599 A \$ 4.3	47,599	D	
Common Stock	02/27/2013		S <sup>(1)</sup>	2,599 D \$ 12.5625	45,000	D	
Common Stock	02/27/2013		M	4,901 A \$ 4.3	49,901	D	
Common Stock	02/27/2013		S <sup>(1)</sup>	4,901 D \$ 12.5544	45,000	D	
	02/28/2013		M	99 A \$ 4.3	45,099	D	

Edgar Filing: Jaen Juan C. - Form 4

Common Stock								
Common Stock	02/28/2013		<u>S<sup>(1)</sup></u>	99	D	\$ 12.56	45,000	D
Common Stock	02/28/2013		M	5,000	A	\$ 4.3	50,000	D
Common Stock	02/28/2013		<u>S<sup>(1)</sup></u>	5,000	D	\$ 13.1353 <u>(4)</u>	45,000	D

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.**

SEC 1474  
(9-02)

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned**  
(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)	7. Title and Amount of Underlying Securities (Instr. 3 and 4)	8. Amount or Number of Shares
Employee Stock Option (right to buy)	\$ 4.3	02/27/2013		M	2,599	<u>(5)</u> 02/06/2017	Common Stock	2,599
Employee Stock Option (right to buy)	\$ 4.3	02/27/2013		M	4,901	<u>(5)</u> 02/06/2017	Common Stock	4,901
Employee Stock Option (right to buy)	\$ 4.3	02/28/2013		M	99	<u>(5)</u> 02/06/2017	Common Stock	99
	\$ 4.3	02/28/2013		M	5,000	<u>(5)</u> 02/06/2017		5,000

Employee  
Stock  
Option  
(right to  
buy)

Common  
Stock

## Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
Jaen Juan C. C/O CHEMOCENTRYX, INC. 850 MAUDE AVENUE MOUNTAIN VIEW, CA 94043			SVP, Drug Discovery & CSO	

## Signatures

/s/ Susan M. Kanaya, as  
Attorney-in-Fact

03/01/2013

\*\*Signature of Reporting Person

Date

## Explanation of Responses:

\* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

(1) The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.

Reflects the weighted average sale price of the shares sold. The shares were sold in multiple trades at prices ranging from \$12.36 to

(2) \$12.85 per share. The Reporting Person will provide to the SEC staff, the issuer or a security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price.

Reflects the weighted average sale price of the shares sold. The shares were sold in multiple trades at prices ranging from \$12.36 to

(3) \$12.85 per share. The Reporting Person will provide to the SEC staff, the issuer or a security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price.

Reflects the weighted average sale price of the shares sold. The shares were sold in multiple trades at prices ranging from \$12.56 to

(4) \$13.40 per share. The Reporting Person will provide to the SEC staff, the issuer or a security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price.

(5) As of February 27, 2013 and prior to this transaction, the option fully vested.

(6) Not applicable.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.